Delcath Systems to Present at LD Micro Virtual Investor Conference on June 10, 2021, at 2:30pm ET

Rhea-AI Summary

Delcath Systems, focused on interventional oncology, announced its management will present at the LD Micro Virtual Investor Conference on June 10, 2021, at 2:30 p.m. ET. This event will feature a live audio webcast accessible through their official link. Delcath’s investigational product, HEPZATO KIT, aims to treat primary and metastatic liver cancers by delivering high-dose chemotherapy while minimizing systemic exposure. Although not FDA-approved in the U.S., it is marketed in Europe under the CHEMOSAT name and has been CE Marked for use.

NEW YORK, June 03, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, today announced that management will present at:

LD Micro Virtual Investor Conference
Date: June 10, 2021
Time: 2:30 p.m. ET – Track 1
Webcast: https://ldmicrojune2021.mysequire.com

A live audio webcast and archive of the event presentation will be available using the webcast link above. For more information on the LD Micro Invitational XI, or to register for the event, please visit https://ldmicrojune2021.mysequire.com.

About Delcath Systems, Inc.

Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. Our investigational product, HEPZATO KIT (melphalan hydrochloride for injection/hepatic delivery system), is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. HEPZATO KIT has not been approved by the U.S. Food & Drug Administration (FDA) for sale in the U.S. In Europe, our system is marketed under the trade name Delcath CHEMOSAT® Hepatic Delivery System for Melphalan (CHEMOSAT) and has been CE Marked and used at major medical centers to treat a wide range of cancers of the liver. CHEMOSAT is being marketed under an exclusive licensing agreement with medac GmbH, a privately held multi-national pharmaceutical company headquartered in Germany that specializes in the treatment and diagnosis of oncological, urological and autoimmune diseases.

Contact:

Delcath Investor Relations

Email: investorrelations@delcath.com

Hayden IR

James Carbonara 
(646)-755-7412 
james@haydenir.com

FAQ

What is Delcath Systems presenting at the LD Micro Virtual Investor Conference?

Delcath Systems will present its management insights and updates on interventional oncology therapies, particularly the HEPZATO KIT.

When is the LD Micro Virtual Investor Conference taking place?

The conference is scheduled for June 10, 2021, at 2:30 p.m. ET.

Where can I access the Delcath Systems presentation from the conference?

The presentation will be available via a live audio webcast at https://ldmicrojune2021.mysequire.com.

What is the purpose of the HEPZATO KIT developed by Delcath Systems?

The HEPZATO KIT is designed to administer high-dose chemotherapy specifically to the liver while controlling side effects.

Is the HEPZATO KIT approved by the FDA for use in the U.S.?

No, the HEPZATO KIT has not been approved by the FDA for sale in the U.S.

Under what name is the HEPZATO KIT marketed in Europe?

In Europe, it is marketed as the CHEMOSAT Hepatic Delivery System for Melphalan.